Lipocine to Present at the Jefferies 2014 Global Healthcare Conference

Lipocine to Present at the Jefferies 2014 Global Healthcare Conference

SALT LAKE CITY, May 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN),
a specialty pharmaceutical company, today announced today announced Mahesh
Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO,
will present a company overview at the Jefferies 2014 Global Healthcare
Conference on Thursday, June 5, 2014 at 2:30 p.m. ET.

A live audio webcast of the presentation will be available via the "Investor
Relations" page of the Lipocine website, Please log on
through Lipocine's website approximately 10 minutes prior to the scheduled
start time. A replay of the webcast will also be archived on Lipocine's
website for 90 days following the presentation.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative
pharmaceutical products for use in men's and women's health using its
proprietary drug delivery technologies. Lipocine's lead product candidate,
LPCN 1021, currently in Phase 3 and is targeted to treat symptoms of low
testosterone for men in need of testosterone replacement therapy. Additional
pipeline candidates include LPCN 1111, a next generation oral testosterone
therapy product, and LPCN 1107, which has the potential to become the first
oral hydroxyprogesterone caproate product indicated for the prevention of
recurrent preterm birth.

Forward-Looking Statements

This release contains "forward looking statements" that are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995 and includes statements that are not historical facts relating to
expectations, clinical trials, the potential uses and benefits of Lipocine's
product candidates, and product development efforts. Investors are cautioned
that all such forward-looking statements involve risks and uncertainties,
including, without limitation, the risks related to the receipt of regulatory
approvals, the results of clinical trials, patient acceptance of Lipocine's
products, the manufacturing and commercialization of Lipocine's products, and
other risks detailed in Lipocine's filings with the U.S. Securities and
Exchange Commission (the "SEC"), including, without limitation, its Form 10-K
and other reports on Form 8-K, all of which can be obtained on the Company's
website at or on the SEC website at Lipocine
assumes no obligation to update or revise publicly any forward-looking
statements contained in this release, except as required by law.

CONTACT: Morgan Brown
         Executive Vice President & Chief Financial Officer
         Phone: (801) 994-7383
         John Woolford
         Phone: (443) 213-0500

Lipocine, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.